We recently published an article titled 11 High Growth Micro-cap Stocks to Buy.
On January 7, Stifel analyst Rick Wise lowered the price target on Outset Medical, Inc. (NASDAQ:OM) to $8 from $14 while maintaining a Buy rating on the shares. The adjustment reflects near-term pressures in MedTech following 2025, though the firm remains constructive on the sector overall for 2026.
Outset Medical, Inc. (NASDAQ:OM) continues to demonstrate steady growth in its dialysis solutions business. In Q3 2025, the company reported revenue of $29.4 million, up 3% year-over-year, and raised its 2025 revenue guidance to a range of $115 million to $120 million. Tablo console sales increased 8% in the quarter, driven by growing hospital demand and an expanding sales pipeline, with opportunities increasing in size by more than 20%. These trends underscore Outset’s ability to capture market share and support long-term growth.
Founded in 2003 and headquartered in San Jose, California, Outset Medical, Inc. (NASDAQ:OM) is focused on transforming dialysis, which is one of healthcare’s largest and most expensive segments, through innovative technology, research, and North American manufacturing operations.
While we acknowledge the potential of OM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy
Disclosure: None.